Manoj K Doss
Overview
Explore the profile of Manoj K Doss including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
484
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tiwari P, Berghella A, Sayali C, Doss M, Barrett F, Yaden D
Psychedelic Med (New Rochelle)
. 2025 Mar;
1(2):74-86.
PMID: 40046726
Background: Emerging literature suggests that classic psychedelics may have efficacy in treating mood and substance use disorders in humans. This has raised questions regarding the primary therapeutic mechanism of these...
2.
Doss M, Kloft L, Mason N, Mallaroni P, Reckweg J, van Oorsouw K, et al.
J Psychopharmacol
. 2024 Nov;
:2698811241301216.
PMID: 39614620
Background: Ayahuasca is an Amazonian brew with 5-HT-dependent psychedelic effects taken by religious groups globally. Recently, psychedelics have been shown to impair the formation of recollections (hippocampal-dependent episodic memory for...
3.
Doss M, DeMarco A, Dunsmoor J, Cisler J, Fonzo G, Nemeroff C
Drugs
. 2024 Oct;
84(11):1419-1443.
PMID: 39455547
Posttraumatic stress disorder (PTSD) is a psychiatric disorder with defining abnormalities in memory, and psychedelics may be promising candidates for the treatment of PTSD given their effects on multiple memory...
4.
Doss M, Mallaroni P, Mason N, Ramaekers J
Biol Psychiatry Cogn Neurosci Neuroimaging
. 2024 Jun;
9(10):1048-1057.
PMID: 38942147
Background: As research on psychedelics (hallucinogenic serotonin receptor 2A agonists) progresses, it is important to delineate the reliability of supposedly unique effects across this drug class. One such effect is...
5.
Barksdale B, Doss M, Fonzo G, Nemeroff C
Neurotherapeutics
. 2024 Jan;
21(2):e00322.
PMID: 38278658
In recent years, psychedelics have generated considerable excitement and interest as potential novel therapeutics for an array of conditions, with the most advanced evidence base in the treatment of certain...
6.
Doss M, Samaha J, Barrett F, Griffiths R, de Wit H, Gallo D, et al.
Psychol Rev
. 2023 Dec;
131(2):523-562.
PMID: 38095937
Despite distinct classes of psychoactive drugs producing putatively unique states of consciousness, there is surprising overlap in terms of their effects on episodic memory and cognition more generally. Episodic memory...
7.
Doss M, de Wit H, Gallo D
Neurosci Biobehav Rev
. 2023 Apr;
150:105188.
PMID: 37085021
Psychoactive drugs modulate learning and emotional processes in ways that could impact their recreational and medical use. Recent work has revealed how drugs impact different stages of processing emotional episodic...
8.
Doss M, Barrett F, Corlett P
ACS Chem Neurosci
. 2022 Aug;
13(17):2540-2543.
PMID: 36001741
A recent paper in found that psilocybin therapy in patients with depression decreased brain network modularity (measured with task-free functional magnetic resonance imaging), an effect supposedly not found with the...
9.
McCulloch D, Knudsen G, Barrett F, Doss M, Carhart-Harris R, Rosas F, et al.
Neurosci Biobehav Rev
. 2022 May;
138:104689.
PMID: 35588933
Clinical research into serotonergic psychedelics is expanding rapidly, showing promising efficacy across myriad disorders. Resting-state functional magnetic resonance imaging (rs-fMRI) is a commonly used strategy to identify psychedelic-induced changes in...
10.
Doss M, Madden M, Gaddis A, Nebel M, Griffiths R, Mathur B, et al.
Brain
. 2021 Dec;
145(2):441-456.
PMID: 34897383
Classic psychedelic drugs such as psilocybin and lysergic acid diethylamide (LSD) have recaptured the imagination of both science and popular culture, and may have efficacy in treating a wide range...